Definition

What Is C. difficile Infection?

Clostridioides difficile (formerly Clostridium difficile) is a spore-forming bacterium that causes severe colon inflammation (colitis) when it overgrows in a disrupted gut microbiome. C. difficile infection (CDI) typically follows antibiotic use, which eliminates protective gut bacteria and allows this opportunistic pathogen to proliferate.

C. difficile produces two main toxins (TcdA and TcdB) that damage colon cells, cause inflammation, and produce characteristic profuse watery diarrhea. The most severe form, pseudomembranous colitis, shows yellow-white plaques on the colon lining. Toxic megacolon and bowel perforation are life-threatening complications.³

The major challenge with CDI is recurrence, ~20-30% of patients have at least one recurrence, and after one recurrence, the rate of further recurrence rises to ~40-65%. The disrupted microbiome remains vulnerable. This makes restoration of healthy microbiome diversity (probiotics, fecal microbiota transplant, dietary support) central to long-term recovery.

💡 Key Insight: The best treatment for C. difficile is prevention, avoid unnecessary antibiotics. When antibiotics are required, take probiotics (S. boulardii) concurrently. For recurrent C. difficile, fecal microbiota transplantation (FMT) cures roughly 85 to 90% of cases after a single treatment, higher with a repeat course, and is now a standard option delivered through a clinician.⁵

Severity of C. difficile Infection

🌱 Non-Severe

WBC <15,000, creatinine <1.5x baseline. Outpatient treatment. Oral fidaxomicin or vancomycin. Excellent prognosis with treatment.

🌗 Severe

WBC ≥15,000 OR creatinine ≥1.5x baseline. Hospitalization usually. Oral vancomycin/fidaxomicin. Monitor for complications.

🌑 Fulminant (Complicated)

Hypotension, shock, ileus, toxic megacolon, perforation. Combination antibiotics. ICU admission. Possible emergency colectomy. High mortality.

Signs & Symptoms

Symptoms of C. difficile Infection

Severity ranges from mild diarrhea to fulminant colitis. Critical to suspect in patients with recent antibiotic exposure.

🔍 Classic Symptoms

💩

Profuse Watery Diarrhea

3+ unformed stools per day, often 10-20. Foul-smelling, sometimes with distinctive odor. May contain mucus. Blood less common but possible.

😣

Crampy Lower Abdominal Pain

Diffuse or lower abdominal crampy pain. May improve briefly after bowel movement. Severe sudden pain suggests complication (toxic megacolon, perforation).

🌡️

Fever & Leukocytosis

38-39°C. WBC often markedly elevated (often >15,000 with significant left shift). Higher WBC indicates more severe disease.

📋

Recent Antibiotic Exposure

Within 8 weeks (sometimes longer). Highest risk: clindamycin, especially community-onset; carbapenems and later-generation cephalosporins, especially hospital-onset; also fluoroquinolones and broad-spectrum penicillins.¹ Diarrhea during/after antibiotics → think C. diff.

⚠️ Severe / Fulminant Red Flags

😵

Hypotension & Shock

Low BP, rapid heart rate, signs of poor perfusion. Septic shock from severe CDI. ICU-level care. Aggressive fluid resuscitation needed.

🎈

Toxic Megacolon

Massive dilation of colon >6cm with systemic toxicity. Imminent perforation risk. Stopping of diarrhea may paradoxically signal worsening (ileus). SURGICAL EMERGENCY.

💢

Peritonitis Signs

Diffuse abdominal pain, rigidity, rebound tenderness, free air on imaging. Indicates perforation. Emergency surgery, often colectomy.

🩸

Lab Abnormalities

WBC >25,000 or <2,000, creatinine doubling, lactate elevation, albumin drop. All indicate severe disease and worse prognosis.

Diagnosis

How C. difficile Is Diagnosed

🔬 Stool Testing

🧪 NAAT (PCR) for tcdB Gene

Highly sensitive but may detect colonization without disease. Combined with toxin test (two-step algorithm) for diagnostic clarity.

🧪 Toxin EIA (A and B)

Detects free toxin in stool. Confirms active infection vs colonization. Less sensitive than PCR but more specific.

🧪 GDH (Glutamate Dehydrogenase)

Highly sensitive screening test. Detects C. difficile presence but not toxin. Used in step-wise algorithms.

⚠️ TEST ONLY DIARRHEA

Don't test formed stool, distinguishes colonization from disease. Don't repeat testing after treatment unless symptoms recur.⁴

🔍 Severity & Workup

🩸 CBC & BMP

WBC count critical for severity classification. Creatinine for renal involvement. Lactate for sepsis/ischemia assessment.

🩸 Albumin, Lactate

Low albumin <3 indicates severe disease. Elevated lactate may indicate ischemic colitis, sepsis, toxic megacolon.

📡 CT Abdomen (Severe Cases)

Colonic wall thickening ("accordion sign"), megacolon, ascites, perforation. Indicated for severe symptoms, abdominal pain, suspected complications.

🔬 Sigmoidoscopy / Colonoscopy

Rarely needed for diagnosis. Pseudomembranes (yellow-white plaques) are diagnostic when present. Reserve for diagnostic dilemma or alternative diagnoses.

Treatment Comparison

Holistic vs. Conventional Treatment

🌿 HOLISTIC

💊 CONVENTIONAL

🌿

Holistic / Functional Approach

PARTNERS with conventional antibiotic treatment. Microbiome restoration is essential to prevent recurrence.

During Treatment

Probiotics (especially S. boulardii) + appropriate antibiotic + hydration

Prevention

Avoid unnecessary antibiotics; take probiotics with required antibiotic courses

Recurrent CDI

FMT (fecal microbiota transplant), ~85 to 90% cure rate, clinician-delivered

Microbiome Restoration

Fiber, fermented foods, polyphenols, diverse plant-based diet

Comprehensive Strategy

Saccharomyces boulardii during treatment: 500mg 2-3x/day. Yeast probiotic, not killed by antibacterials. The evidence is better for ordinary antibiotic-associated diarrhea than for C. difficile specifically: PLACIDE randomized 2,981 patients and found no effect on C. difficile diarrhea, and the 2021 ACG guideline recommends against probiotics for preventing it. Reasonable to try, not established.⁶
L. rhamnosus GG + L. acidophilus combination: also effective. 10-20 billion CFU multi-strain probiotic.
Aggressive hydration: oral rehydration solutions, electrolyte replacement
Stop unnecessary antibiotics: discontinue any non-essential antibiotic. Even when treating CDI itself, avoid additional unnecessary antibiotics.
Stop / minimize PPIs: proton pump inhibitors increase CDI risk significantly. Discontinue if possible.
Avoid loperamide: anti-diarrheals can cause toxin retention, increase risk of toxic megacolon
Microbiome restoration nutrition: diverse vegetables, fermented foods (yogurt, kefir, sauerkraut, kimchi), prebiotic fibers (onions, garlic, leeks, asparagus, bananas)
Bone broth: supports gut healing, hydration, easily tolerated
L-glutamine: 5-15g/day supports gut barrier repair
Vitamin D optimization: deficiency associated with CDI severity and recurrence
Fecal Microbiota Transplant (FMT): for recurrent CDI, a single treatment cures roughly 85 to 90%. Increasingly available via specialty centers.
Hand hygiene: SOAP AND WATER (alcohol sanitizers don't kill C. diff spores). Critical for preventing spread.
Environmental disinfection: bleach-based cleaners required for C. diff spores
Address comorbid conditions: IBD, immunocompromise, age, these increase risk
Long-term microbiome support: continue probiotics 2-3 months after treatment; diverse fiber intake; minimize future antibiotic exposure

✅ FMT Is Game-Changing: For recurrent C. difficile, fecal microbiota transplantation cures roughly 85 to 90% after one treatment, against about 30% for a vancomycin course in recurrent disease. Now available as an oral microbiota product (Vowst, fecal microbiota spores), enema, or colonoscopy. If you have recurrent CDI, ask about FMT, it's a paradigm shift in treatment.

💊

Conventional / Medical Approach

Fidaxomicin or vancomycin first-line. FMT for recurrent disease. Bezlotoxumab for prevention.

First Episode

Fidaxomicin 200mg BID × 10 days (preferred) OR vancomycin 125mg QID × 10 days

Recurrent (1st)

Fidaxomicin or pulsed/tapered vancomycin OR vancomycin + bezlotoxumab

Multiple Recurrences

FMT (fecal microbiota transplant), capsule (Vowst, Rebyota), enema, or colonoscopy delivery

Fulminant

Vancomycin (oral high dose) + IV metronidazole; possible vancomycin enema; emergency colectomy if severe

Modern Treatment Algorithms

First episode, non-severe: Fidaxomicin 200mg PO BID × 10 days (preferred, lower recurrence) OR vancomycin 125mg PO QID × 10 days. Metronidazole no longer first-line.
First episode, severe: Same as above but with closer monitoring. May need IV fluids, hospitalization.
First recurrence: Fidaxomicin (if not used first), OR pulsed/tapered vancomycin (125mg QID × 14d, then BID × 7d, then daily × 7d, then every 2-3 days × 2-8 weeks). Consider adding bezlotoxumab.
Second+ recurrence: FMT recommended. Available as Vowst (oral capsules), Rebyota (enema), or via colonoscopy/NG tube at specialty centers.
Bezlotoxumab (Zinplava): monoclonal antibody against toxin B. Given as single IV infusion. Reduces recurrence ~10% absolute risk reduction. Used with antibiotic for high-recurrence-risk patients.
Fulminant CDI: vancomycin 500mg PO/NG QID + IV metronidazole 500mg q8h. Consider rectal vancomycin enemas if ileus. Surgical consultation urgent, emergency colectomy may be life-saving.
STOP inciting antibiotics: critical to discontinue or switch unnecessary antibiotics
STOP PPIs: if possible; they increase CDI risk and recurrence
AVOID anti-motility agents: loperamide can worsen, cause toxin retention
Hospital isolation precautions: contact precautions, single room, soap and water for handwashing
Vowst (oral microbiome capsules): NEW (2023), orally administered live biotherapeutic. 4 capsules daily × 3 days after vancomycin completion.
Surgical options for fulminant CDI: total abdominal colectomy with end ileostomy; diverting loop ileostomy with vancomycin lavage (newer, organ-preserving option)

⚠️ Important Treatment Updates: Metronidazole is NO LONGER first-line, inferior to vancomycin and fidaxomicin. Fidaxomicin is preferred over vancomycin when available (lower recurrence rate). FMT is curative for recurrent disease but cost and access vary, new oral options (Vowst) make this easier.

Nutritional Strategy

Diet for C. difficile

Hydration + easy digestion during acute illness; aggressive microbiome restoration during recovery.

✅ Prioritize:

💧 Aggressive Hydration

Oral rehydration solutions, water, broths. Replace lost fluids and electrolytes. Sip frequently throughout day.

🥣 Bone Broth & Soups

Provide electrolytes, amino acids, gentle hydration. Easy to tolerate during illness. Add ginger for nausea.

🌱 Fermented Foods (As Tolerated)

Plain yogurt, kefir, sauerkraut, kimchi, miso. Restore microbiome diversity. Increase gradually during recovery.

🥬 Prebiotic Foods (Recovery)

Onions, garlic, leeks, asparagus, bananas, oats. Feed beneficial bacteria. Add gradually as recovering.

🥚 Adequate Protein

Eggs, fish, poultry. Support recovery. Easily digestible protein sources during illness.

❌ Avoid:

💊 Unnecessary Antibiotics

Single most important prevention. Don't use antibiotics for viral infections. Question every antibiotic prescription.

💊 PPIs (When Possible)

Proton pump inhibitors increase CDI risk significantly. Discuss discontinuation with doctor. Try H2 blockers if reducing stomach acid needed.

🍔 Ultra-Processed Foods

Damage microbiome diversity. Emulsifiers and additives. Replace with whole foods during recovery.

🍬 Refined Sugar

Feeds dysbiosis, suppresses beneficial bacteria. Limit during recovery to favor microbiome restoration.

🥃 Alcohol

Disrupts microbiome, irritates gut. Avoid during illness and 2-4 weeks during recovery.

Supplement Protocol

Evidence-Based Supplements

Among the microbiome-support options here, S. boulardii has the most evidence behind it, which is a statement about this list and not a comparison with antibiotics or FMT. Multi-faceted microbiome support for recovery.

Supplement	Mechanism & Evidence	Suggested Dose	Timing	Notes
Saccharomyces boulardii	Best-studied probiotic for C. difficile. Reduces recurrence ~50%. Resistant to antibiotics.	500mg 2-3x/day during & 4-8 weeks after treatment	Throughout day	Yeast, not affected by antibiotics. Can take during active antibiotic treatment.
L. rhamnosus GG + L. acidophilus	Multi-strain probiotic. Reduces antibiotic-associated diarrhea and C. difficile risk.	10-30 billion CFU multi-strain, 2x/day	2 hours away from antibiotics	Continue 2-3 months after treatment.
L-Glutamine	Restores intestinal barrier function. Supports recovery of damaged gut lining.	5-15g/day	Between meals	Especially helpful post-CDI to repair barrier dysfunction.
Vitamin D3	Deficiency associated with CDI severity and recurrence. Immune modulator.	Test 25-OH-D first and set the dose with your clinician (titrate to 40 to 60 ng/mL, the Endocrine Society's preferred range)	With fat meal	Correcting a deficiency may need a higher initial dose, decided by your clinician.
Zinc	Supports immune function and gut healing. Often deficient with diarrhea.	15-30mg/day	With food	2-4 weeks during recovery. Don't exceed long-term.
Bovine Colostrum / Hyperimmune Bovine Colostrum	Provides immunoglobulins against C. difficile toxins. Some evidence for refractory cases.	20-60g/day	Empty stomach	Limited but interesting evidence. Discuss with specialist.
N-Acetyl Cysteine (NAC)	Glutathione precursor; glutathione is used in Phase II conjugation. Anti-inflammatory.	600-1,200mg/day	Empty stomach	Supports recovery, well-tolerated.
Prebiotics (GOS, FOS, Inulin)	Feed beneficial gut bacteria. Help restore healthy microbiome diversity.	2-10g/day, gradually increase	With or between meals	Start low, can worsen symptoms if gas/bloating develops.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed 27 August 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.⁸ Read this first. C. difficile is a bacterial infection treated with antibiotics, specifically vancomycin or fidaxomicin. Nothing on this page treats it. Do not stop the course early because you feel better, because incomplete treatment is a common route to relapse. Severe C. difficile can progress to toxic megacolon and perforation, so worsening pain, abdominal distension, a swollen tender abdomen, fever, or a drop in the number of stools after severe diarrhoea are reasons to be seen urgently rather than signs of improvement. The microbiome support on this page is for reducing the chance of recurrence after treatment, and for recovering afterwards. It is an adjunct to antibiotics and never a replacement for them.

On the mechanism: C. difficile is an opportunistic infection that follows disruption of the normal colonic microbiota, most often by antibiotics. The ranking depends on where the infection was acquired, which is easy to miss. For infection associated with a healthcare facility, a 2021 systematic review and meta-analysis found carbapenems and third- and fourth-generation cephalosporins most strongly associated, with cases more than twice as likely to have had recent exposure to them, and only modest associations for fluoroquinolones, clindamycin and beta-lactamase-inhibitor penicillins, PubMed 33787887. In community-onset disease clindamycin carries the largest effect of any antibiotic: an odds ratio of 16.8 against no antibiotic exposure, PubMed 23478961, and the highest risk of any outpatient antibiotic across 36.6 million patients, PubMed 36377887. Nearly any antibacterial can precipitate it. Advanced age, hospitalisation, gastric acid suppression and immunosuppression raise risk further. ↩
On treatment: current guidance from the Infectious Diseases Society of America and the American College of Gastroenterology places oral vancomycin and fidaxomicin as first-line therapy, with fidaxomicin associated with lower recurrence. Metronidazole has been demoted and is now reserved for situations where the preferred agents are unavailable. Bezlotoxumab, a monoclonal antibody against toxin B, can be added to reduce recurrence in selected high-risk patients. Recurrence after a first episode is common, in the region of 20 to 25%, and rises with each subsequent episode. ↩
On severity: severe and fulminant disease is marked by hypotension, shock, ileus or toxic megacolon, and is treated differently from ordinary infection, PubMed 42538089. Antimotility agents such as loperamide are generally avoided in acute C. difficile colitis because slowing transit retains toxin. Paradoxical improvement in diarrhoea alongside worsening abdominal distension is a warning sign, not a recovery sign. ↩
On testing: a positive toxin test in someone without diarrhoea usually reflects colonisation rather than infection, and treating asymptomatic carriers is not recommended. Repeat testing to prove cure is also not recommended, because the assay can stay positive for weeks after symptoms resolve. This matters because it prevents unnecessary further antibiotic courses, which are themselves a risk factor. ↩
On fecal microbiota transplantation: FMT is well established for recurrent C. difficile, with cure rates above 90% in observational studies, PubMed 37274301. That meta-analysis is worth reading for its main point rather than its headline: efficacy measured in randomised controlled trials is lower than the observational figure, so treat the commonly quoted number as the optimistic end. It is recommended after multiple recurrences rather than for a first episode. Two FDA-approved microbiota-based products are now available for preventing recurrence in adults, delivered rectally and orally respectively, which places this firmly within prescribed medical care. ↩
On probiotics, including the trial that did not work. Saccharomyces boulardii and multi-strain probiotics have reasonable evidence for reducing antibiotic-associated diarrhoea in general. For C. difficile specifically the picture is weaker. PLACIDE (Allen SJ, et al. Lancet. 2013;382:1249–1257) randomized 2,981 older inpatients on antibiotics to a multi-strain preparation or placebo and found no significant reduction in C. difficile diarrhoea. The 2021 American College of Gastroenterology guideline recommends against probiotics for prevention of C. difficile infection. Meta-analyses are more favourable than the largest single trial, which is usually a reason for caution rather than confidence. This page keeps probiotics because the downside is small and the recovery rationale is reasonable, but it should not be read as established. ↩
On do-it-yourself fecal transplant. The FDA has issued safety communications after transmission of drug-resistant organisms through inadequately screened donor stool, including invasive infection and a patient death, and subsequently after transmission of pathogenic E. coli. Clinical FMT depends on donor screening, laboratory testing and quarantine, and the screening is not an administrative formality but the part that makes it safe. Home FMT using stool from a friend or relative bypasses all of it. Anyone with recurrent C. difficile should be asking for referral to a gastroenterologist, who now has both FMT and approved microbiota products available. ↩
National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic.